Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	74	34	16	41	94	21
Market Cap Growth	821.80%	112.09%	-60.44%	-57.05%	346.77%	186.68%
Enterprise Value	53	35	-0	2	77	10
Last Close Price	2.11	2.77	1.71	6.64	20.80	22.50
PE Ratio	-	-0.89	-0.42	-1.53	-2.73	-1.23
PB Ratio	7.70	-25.10	1.03	1.23	1.72	2.33
P/FCF Ratio	-3.26	-1.02	-0.63	-1.79	-6.75	-1.80
P/OCF Ratio	-3.33	-1.05	-0.64	-1.80	-6.78	-1.81
EV/EBITDA Ratio	-2.99	-0.90	0.01	-0.08	-5.11	-0.68
EV/EBIT Ratio	-2.97	-0.90	0.01	-0.08	-5.06	-0.67
EV/FCF Ratio	-3.18	-1.05	0.01	-0.09	-5.53	-0.81
Debt / Equity Ratio	0.02	-0.41	0.04	0.01	0.01	0.06
Debt / FCF Ratio	-0.01	-0.02	-0.02	-0.01	-0.03	-0.05
Quick Ratio	2.46	0.74	3.59	8.95	16.04	3.83
Current Ratio	2.54	0.81	3.71	9.16	16.26	4.11
Return on Equity (ROE)	-304.38%	-536.81%	-117.82%	-54.92%	-47.28%	-126.28%
Return on Assets (ROA)	-91.47%	-144.66%	-61.26%	-31.47%	-26.95%	-64.91%
Return on Capital (ROIC)	-152.45%	-318.13%	-72.82%	-34.06%	-29.49%	-77.56%
Earnings Yield	-67.40%	-111.59%	-178.21%	-59.46%	-15.98%	-66.66%
FCF Yield	-52.14%	-97.66%	-158.57%	-55.98%	-14.82%	-55.43%
Buyback Yield / Dilution	-100.67%	-73.22%	-27.09%	-180.20%	-158.14%	-159.12%
Total Shareholder Return	-100.67%	-73.22%	-27.09%	-180.20%	-158.14%	-159.12%

Source: S&P Capital IQ. Standard template. Financial Sources.